Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 447-452

  Patel, Manish ^a   Ardalan, Katherine ^a   Hochman, Ian ^a   Tian, Er Ming ^a   Ardalan, Bach ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bolus; DNA; Fluorouracil; Infusion; RNA

Indexed keywords

CELL DNA; FLUOROURACIL; RNA; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ARTICLE; BOLUS INJECTION; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MELANOMA; RNA, NEOPLASM; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0037236134     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schmoll HJ, Buchele T, Grothey A and Dempke W: Where do we stand with 5-Fluorouracil? Semin Oncol 26: 589-605, 1999.
2. Sun D, Urrabaz R, Kelly S, Nguyen M and Weitman S: Enhancement of DNA ligase I level by gemcitabine in human cancer cells. Clin Cancer Res 8(4): 1189-1195, 2002.
3. Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, Guereio G, Bellanca L and Rausa L: The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18(3A): 1515-1520, 1998.
4. Shuey DL, Setzer RW, Lau C, Zucker RM, Elstein KH, Narotsky MG, Kavlock RJ and Rogers JM: Biological modeling of 5-fluorouracil developmental toxicity. Toxicology 102(1-2): 207-213, 1995.
5. Peters GJ, Van Groeningen CJ, Laurensse EJ and Pinedo HM: Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxy-uridine-5′-monophosphate. Eur J Cancer 27(3): 263-267, 1991.
6. Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6(10): 1653-1664, 1988.
7. Langenbach RJ, Danenberg PV and Heidelberger C: Thymidylate Synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyridylate. Biochem Biophys Res Commun 48: 1565-1571, 1972.
8. Geoffroy FJ, Allegra CJ, Sinha B and Grem JL: Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res 6(12): 581-591, 1994.
9. Glazer RI and Lloyd LS: Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 9: 468-473, 1982.
10. Mandel HG, Klubes P and Fernandes DJ: Studies of the antitumor action of 5-fluorouracil (FU). Bull Cancer 66(1): 49-54, 1979.
11. Houghton JA, Houghton PJ and Wooten RS: Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39(7 Pt 1): 2406-2413, 1979.
12. Kufe DW and Major PP: 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256(19): 9802-9805, 1981.
13. Dolnick BJ and Pink JJ: 5-Fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells. J Biol Chem 258(21): 13299-13306, 1983.
14. Haggard ME, Cangir A, Ragab AH, Komp D, Falletta J and Humphrey GB: 5-Fluorouracil in childhood solid tumors. Cancer Treat Rep 61(1): 69-71, 1977.
15. Ardalan B, Singh G and Silberman H: A randomized phase I and II study of short-term infusion of high dose fluorouracil with and without N-(phosphonactely)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6(6): 1053-1058, 1988.
16. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ and Benson AB 3rd: Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-1-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24 hr infusion schedule-an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19(9): 2413-2421, 2001.
17. Howell JD, Warren HW, Anderson JH, Kerr DJ and McArdle CS: Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer. Eur J Surg 165(7): 652-658, 1999.
18. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L and Kanz L: Paclitaxel and weekly 24 hr infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 24(6 Suppl 19): S19-96-S19-100, 1997.
19. Lokich J, Chaffey J and Neptune W: Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. Cancer 64(5): 1021-1025, 1989.
20. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D and Jolivet J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260(17): 9720-9726, 1985.
21. Ives DH, Durham JP and Tucker VS: Rapid determination of nucleoside kinase and nucleotidase activities with tritium labeled substrates. Anal Biochem 28(1): 192-205, 1969.
22. Maniatis T, Fritsch EF and Sambrook J: Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor, 1982.
23. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156-159, 1987.
24. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7(4): 425-432, 1989.
25. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37(13): 1681-1687, 2001.
26. Nita ME, Tominaga O, Nagawa H, Tsuruo T and Muto T: Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45(24): 2117-2122, 1998.